Evidence map›Paper›PMID 29029546›Full record

ReviewOncotarget2017

Bladder cancer stem cells: clonal origin and therapeutic perspectives.

Yi Li, Kaisu Lin, Zhao Yang, Ning Han, Xiaofang Quan, Xiangyang Guo, Chong Li

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Anti-cancer activity of Chaga mushroom (Frontiers in pharmacology · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Yi LiDepartment of Anesthesiology, Peking University Third Hospital, Beijing, China.
Kaisu LinDepartment of Oncology, the Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, China.
Zhao YangCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Ning HanDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Xiaofang QuanCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Xiangyang GuoDepartment of Anesthesiology, Peking University Third Hospital, Beijing, China.
Chong LiCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Institute of Biophysics · CNPeking University · CNChina Pharmaceutical University · CNChinese Academy of Sciences · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we review the origin and therapeutic perspectives of bladder cancer stem cells (BCSCs), which are integral to the initiation, high recurrence and chemoresistance of bladder cancer. BCSCs are heterogenous and originate from multiple cell types, including urothelial stem cells and differentiated cell types, including basal, intermediate stratum and umbrella cells. Cell surface markers, including CD44, CD67LR, EMA, ALDH1A1 and BCMab1, are used to identify and isolate BCSCs. The Hedgehog, Notch, Wnt and JAK-STAT signaling pathways play key roles in maintaining the stemness, self-renewal and proliferative potential of BCSCs. High expression of ABC transporters, acetaldehyde dehydrogenase, antioxidants and apoptosis resistance proteins in BCSCs play a critical role in chemoresistance. Consequently, a greater understanding of the biology of BCSCs will be important for identifying effective therapeutic targets to improve clinical outcomes for bladder cancer patients.

Indexed as

BCSCsbladder cancercancer stem cell

Identifiers

PMID29029546
PMCPMC5630446
OpenAlexW2734838830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.